● The deployment of streamlined and resilient solutions
with a patient-centric approach is likely to foster innovation
in the vaccine supply chain industry.
● Strengthening capabilities in needle-free delivery and
the growing focus on novel disease indications such as
cytomegalovirus and glioblastoma are anticipated to open
new growth avenues in the traditional vaccine industry.
● The strategic procurement of vaccines by proactive
government authorities as part of systemic immunization
programs will reduce vaccine prices and improve health
outcomes across the globe.